ArticleFrontiers in immunology2023

A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models.

Kamel Chettab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.